Frankfurt Cargo Services Expand Pharma Presence with New Facility

Why It Matters

The expanded, certified facility strengthens FCS’s ability to meet rising demand for secure, temperature‑controlled pharmaceutical shipments, enhancing its competitive edge in Europe’s air cargo market.

Key Takeaways

• New Pharma Center adds ~3,300 sq m temperature‑controlled space.
• Facility is CEIV and GDP certified for pharma cargo.
• Handles both room‑temperature (15‑25 °C) and cool (2‑8 °C) storage.
• Enables pallet assembly, active loading unit storage, and direct loose freight.
• Supports rapid growth in pharma logistics at Frankfurt hub.

Pulse Analysis

The pharmaceutical cargo segment has become a bellwether for air freight profitability, driven by the surge in biologics, vaccines, and temperature‑sensitive therapies. Operators that can guarantee CEIV (Center of Excellence for Independent Validators) and GDP (Good Distribution Practice) compliance gain the trust of manufacturers and regulators, especially in Europe’s largest logistics gateway, Frankfurt Airport. By investing in a purpose‑built Pharma Center, FCS aligns itself with the stringent standards that shippers now demand.

The new centre’s 3,300 sq m of climate‑controlled space enables FCS to handle both Controlled Room Temperature (15‑25 °C) and Controlled Cool (2‑8 °C) cargo in a single location. Its ability to receive loose freight directly into temperature‑controlled zones, assemble entire pallets, and store active loading units such as containers with dedicated power supplies streamlines the supply chain, reducing dwell time and handling risk. Customers benefit from a one‑stop solution that minimizes transfers and maintains product integrity from receipt to dispatch.

Strategically, the facility positions FCS to capture a larger share of the fast‑growing pharma logistics market, where capacity constraints and regulatory scrutiny are intensifying. With Thomas Schürmann at the helm—bringing experience from Etihad Airways—the company is poised to leverage the expanded footprint for new partnerships and higher service tiers. As pharmaceutical manufacturers increasingly favor hub‑and‑spoke models, FCS’s enhanced capabilities could translate into higher revenue per kilogram and stronger bargaining power against competing cargo handlers.